Yahoo · Nov 3, 2026
TEM Q3 Earnings Call Highlights Growth and 2027 Pricing Upside
Tempus AI raises its 2026 revenue outlook as oncology demand, expanding data partnerships and reimbursement-driven pricing gains fuel growth prospects for 2027.
PS
NASDAQ · PSNL
Personalis, Inc.
Healthcare · Medical - Diagnostics & Research
$15.75
Up+$0.04 (+0.25%)
Updated Nov 5, 2026, 1:16 AM
SID Score
5.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 824.5M
- P/E ratio
- -11.15
- Dividend yield
- 0.00%
- 52-week range
- $4.96 – $18.89
- Volume
- 2.93M
- Avg. volume
- 1.34M
Price performance · PSNL
PSNL price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
PSNL closed at $15.75 after 20 trading sessions, down 1.56% for the selected period.
- Last close
- $15.75
- Period change
- -1.56%
- Period low
- $15.65
- Period high
- $16.06
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $15.90 | $15.97 | $15.75 | $15.75 | 2.93M |
| Nov 2, 2026 | $15.92 | $15.93 | $15.745 | $15.76 | 2.2M |
| Oct 30, 2026 | $15.86 | $15.94 | $15.645 | $15.82 | 2.36M |
| Oct 29, 2026 | $15.98 | $16.05 | $15.88 | $15.925 | 749.24K |
| Oct 28, 2026 | $15.93 | $16.11 | $15.86 | $16.00 | 1.23M |
| Oct 27, 2026 | $15.86 | $16.13 | $15.80 | $15.98 | 1.83M |
| Oct 26, 2026 | $15.81 | $15.985 | $15.77 | $15.88 | 1.14M |
| Oct 23, 2026 | $15.73 | $15.89 | $15.67 | $15.85 | 1.12M |
| Oct 22, 2026 | $15.90 | $15.96 | $15.625 | $15.82 | 2.69M |
| Oct 21, 2026 | $15.755 | $16.115 | $15.755 | $15.90 | 2.79M |
| Oct 20, 2026 | $15.94 | $16.00 | $15.85 | $15.94 | 2.38M |
| Oct 19, 2026 | $15.83 | $16.0194 | $15.745 | $15.88 | 3.16M |
| Oct 16, 2026 | $15.86 | $16.00 | $15.505 | $15.65 | 3.31M |
| Oct 15, 2026 | $15.88 | $16.08 | $15.83 | $15.93 | 2.14M |
| Oct 14, 2026 | $15.71 | $16.00 | $15.68 | $15.90 | 3.26M |
| Oct 13, 2026 | $15.82 | $15.97 | $15.79 | $15.85 | 3.82M |
| Oct 12, 2026 | $16.01 | $16.17 | $15.795 | $15.80 | 2.25M |
| Oct 9, 2026 | $16.19 | $16.24 | $15.975 | $16.00 | 1.84M |
| Oct 8, 2026 | $15.92 | $16.20 | $15.92 | $16.06 | 1.47M |
| Oct 7, 2026 | $15.775 | $16.10 | $15.68 | $16.00 | 3.82M |
Latest PSNL news
The latest Smart Investors Daily articles mentioning PSNL.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PSNL research
Overview
Company profile and research snapshot.
Company profile
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $9.50
- Implied upside
- —
- Analysts
- 13
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 6, 2026 | BTIG | Neutral | — |
| Jul 20, 2026 | Needham | Hold | — |
| Jul 20, 2026 | BTIG | Buy | — |
| Jul 20, 2026 | Lake Street | Hold | — |
| Jul 17, 2026 | Needham | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Nov 2, 2026
Do You Own Tempus AI Without Knowing It? Check These ETFs After Its Earnings Surge
Tempus AI surged double digits after a blowout earnings report, and some investors felt every point of that move without ever buying a single share. Check whether a fund you already own has been riding along.
Yahoo · Nov 2, 2026
What Tempus AI (TEM) Said on Its Q3 Earnings Call
Tempus AI (NASDAQ:TEM) reported third-quarter 2026 revenue of $411.5 million, up 23% from a year earlier, as growth in oncology diagnostics and data-and-applications services continued to drive results. The company also raised its full-year revenue outlook and said it generated positive adjusted EBI
Yahoo · Nov 2, 2026
Tempus AI’s Cancer Screen Business Drives Revenue Up 23%, While a Major Purchase Draws Closer
Tempus AI reported better-than-expected third-quarter earnings.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
